Wegovy, Ozempic, and Mounjaro have generated enormous excitement — and for good reason. They deliver substantial weight loss, and the research shows impressive effects on everything from blood sugar control to heart health. But there is one side effect that often gets overlooked in the enthusiasm: what happens to your bones?

The short answer is that GLP-1 medications can reduce bone density, and over time this may increase the risk of osteoporosis and fractures. This is not a reason to panic, but it is something worth knowing and planning for. In this article we walk through what the research shows, who is most at risk, and what you can do to protect your skeleton.

What does the research show?

In recent years, solid evidence has emerged that GLP-1 medications can have a negative impact on bone density. A 2024 randomized controlled trial (Hansen et al.) followed participants for 52 weeks and found that semaglutide reduced hip bone mineral density (BMD) by 2.6% and lumbar spine BMD by 2.1% compared to placebo. That may not sound like much, but for people who already have low bone density, even a small decline can have real consequences.

A separate 2024 study published in JAMA (195 adults, 52 weeks) found an important and encouraging result: participants who combined GLP-1 treatment with regular exercise maintained their bone density — while those who took the medication without an exercise program saw it decline. This shows that exercise is not just a nice addition, but a genuine protective factor.

A larger observational study of around 150,000 adults found that approximately 4% of GLP-1 users developed osteoporosis over the study period, compared to around 3% in the comparison group — a relative risk increase of roughly one third. It is not alarming in absolute terms, but it is a real difference worth being aware of.

Wegovy's prescribing information also includes a notable warning: hip fractures were reported in 1% of women in the trial versus 0.2% on placebo — a fivefold difference in frequency, even though the absolute numbers are small.

Why does GLP-1 medication affect bones?

There are two main mechanisms at work:

There is also some good news from the research: GLP-1 receptors are found directly on osteoblasts (the cells that build new bone), and some studies suggest that GLP-1 receptor agonists may have a direct positive effect on bone formation. The picture is therefore not entirely negative, and research in this area is ongoing.

Who is most at risk?

Not everyone needs to worry equally. The groups with the greatest reason to pay attention are:

How to protect your bones

The good news is that bone loss during GLP-1 treatment is far from inevitable. Here are the most effective protective steps:

When to talk to your doctor

It is always a good idea to mention bone health to your doctor when starting GLP-1 treatment — but it is especially important if you:

Your doctor may consider ordering a DEXA scan (bone density measurement) at the start of treatment and again after a year to track changes. In some cases, bone-protecting medication may be appropriate alongside your GLP-1 treatment.

Keeping perspective: the benefits still weigh heavily

It is important to keep the bigger picture in mind. GLP-1 medications have well-documented benefits for obesity, type 2 diabetes, cardiovascular disease, and a wide range of related conditions — and the absolute risks of bone harm are relatively low for most users. Bone health is an area to monitor and actively protect, not a reason to avoid treatment altogether.

With the right approach — regular exercise, good nutrition, and ongoing dialogue with your doctor — most people can continue treatment confidently while keeping their skeleton in good shape.

Sources